explore -WSS

explore

author：fashion 2025-09-09 03:38:35 - browse：697

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： The Bio Revolution is changing business and society

entertainment

WSS

U.S. death rates show how politics are affecting public health

J&J reports mixed data on next

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

J&J reports mixed data on next

Why some fertility treatments produce more boy babies

Why we need mandatory labeling of GMO products

Wikipedia

explore

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Should insurance cover cosmetic surgery?

In age of alternative facts, a scholarly course on calling out crap

Why some fertility treatments produce more boy babies

Affirmative action in medical school literally saved lives

What causes an itch? Researchers may have solved the mystery

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Guardant Health colon cancer test endorsed by FDA advisory panel

As demand for Covid shots wanes, Moderna seeks its next success

Louisiana bill approved classifying abortion pills as controlled substances

focus

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Decentralized clinical trials need collaboration to achieve wider use

Spinal cord stimulation reduces pain in amputees, study finds

Why sickle cell disease is getting the first CRISPR treatment

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Guardant Health colon cancer test endorsed by FDA advisory panel

focus

entertainment

hotspot

explore